Literature DB >> 22918967

Coordinated regulation of murine cardiomyocyte contractility by nanomolar (-)-epigallocatechin-3-gallate, the major green tea catechin.

Wei Feng1, Hyun Seok Hwang, Dmytro O Kryshtal, Tao Yang, Isela T Padilla, Asheesh K Tiwary, Birgit Puschner, Isaac N Pessah, Björn C Knollmann.   

Abstract

Green tea polyphenolic catechins exhibit biological activity in a wide variety of cell types. Although reports in the lay and scientific literature suggest therapeutic potential for improving cardiovascular health, the underlying molecular mechanisms of action remain unclear. Previous studies have implicated a wide range of molecular targets in cardiac muscle for the major green tea catechin, (-)-epigallocatechin-3-gallate (EGCG), but effects were observed only at micromolar concentrations of unclear clinical relevance. Here, we report that nanomolar concentrations of EGCG significantly enhance contractility of intact murine myocytes by increasing electrically evoked Ca(2+) transients, sarcoplasmic reticulum (SR) Ca(2+) content, and ryanodine receptor type 2 (RyR2) channel open probability. Voltage-clamp experiments demonstrate that 10 nM EGCG significantly inhibits the Na(+)-Ca(2+) exchanger. Of importance, other Na(+) and Ca(2+) handling proteins such as Ca(2+)-ATPase, Na(+)-H(+) exchanger, and Na(+)-K(+)-ATPase were not affected by EGCG ≤ 1 μM. Thus, nanomolar EGCG increases contractility in intact myocytes by coordinately modulating SR Ca(2+) loading, RyR2-mediated Ca(2+) release, and Na(+)-Ca(2+) exchange. Inhibition of Na(+)-K(+)-ATPase activity probably contributes to the positive inotropic effects observed at EGCG concentrations >1 μM. These newly recognized actions of nanomolar and micromolar EGCG should be considered when the therapeutic and toxicological potential of green tea supplementation is evaluated and may provide a novel therapeutic strategy for improving contractile function in heart failure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22918967      PMCID: PMC3477230          DOI: 10.1124/mol.112.079707

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  All human Na(+)-K(+)-ATPase alpha-subunit isoforms have a similar affinity for cardiac glycosides.

Authors:  J Wang; J B Velotta; A A McDonough; R A Farley
Journal:  Am J Physiol Cell Physiol       Date:  2001-10       Impact factor: 4.249

2.  Green tea catechins are potent sensitizers of ryanodine receptor type 1 (RyR1).

Authors:  Wei Feng; Gennady Cherednichenko; Chris W Ward; Isela T Padilla; Elaine Cabrales; José R Lopez; José M Eltit; Paul D Allen; Isaac N Pessah
Journal:  Biochem Pharmacol       Date:  2010-05-22       Impact factor: 5.858

3.  In vitro electrocardiographic and cardiac ion channel effects of (-)-epigallocatechin-3-gallate, the main catechin of green tea.

Authors:  Jiesheng Kang; Hsien Cheng; Junzhi Ji; Josephine Incardona; David Rampe
Journal:  J Pharmacol Exp Ther       Date:  2010-05-18       Impact factor: 4.030

4.  Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Björn C Knollmann; Nagesh Chopra; Thinn Hlaing; Brandy Akin; Tao Yang; Kristen Ettensohn; Barbara E C Knollmann; Kenneth D Horton; Neil J Weissman; Izabela Holinstat; Wei Zhang; Dan M Roden; Larry R Jones; Clara Franzini-Armstrong; Karl Pfeifer
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

5.  Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.

Authors:  H-H Sherry Chow; Iman A Hakim; Donna R Vining; James A Crowell; James Ranger-Moore; Wade M Chew; Catherine A Celaya; Steven R Rodney; Yukihiko Hara; David S Alberts
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

Review 6.  Molecular targets of tea polyphenols in the cardiovascular system.

Authors:  Verena Stangl; Henryk Dreger; Karl Stangl; Mario Lorenz
Journal:  Cardiovasc Res       Date:  2006-09-01       Impact factor: 10.787

Review 7.  Potential role of green tea catechins in various disease therapies: progress and promise.

Authors:  Judith C W Mak
Journal:  Clin Exp Pharmacol Physiol       Date:  2012-03       Impact factor: 2.557

Review 8.  Metabolism of green tea catechins: an overview.

Authors:  Wan Yong Feng
Journal:  Curr Drug Metab       Date:  2006-10       Impact factor: 3.731

9.  Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue.

Authors:  M Suganuma; S Okabe; M Oniyama; Y Tada; H Ito; H Fujiki
Journal:  Carcinogenesis       Date:  1998-10       Impact factor: 4.944

10.  The calcium-ryanodine receptor complex of skeletal and cardiac muscle.

Authors:  I N Pessah; A L Waterhouse; J E Casida
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

View more
  17 in total

1.  Sarcomere neutralization in inherited cardiomyopathy: small-molecule proof-of-concept to correct hyper-Ca2+-sensitive myofilaments.

Authors:  Brian R Thompson; Joshua Martindale; Joseph M Metzger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-05-13       Impact factor: 4.733

2.  Isolation and physiological analysis of mouse cardiomyocytes.

Authors:  Gretchen M Roth; David M Bader; Elise R Pfaltzgraff
Journal:  J Vis Exp       Date:  2014-09-07       Impact factor: 1.355

3.  Uncoupling of myofilament Ca2+ sensitivity from troponin I phosphorylation by mutations can be reversed by epigallocatechin-3-gallate.

Authors:  Maria Papadaki; Petr G Vikhorev; Steven B Marston; Andrew E Messer
Journal:  Cardiovasc Res       Date:  2015-06-24       Impact factor: 10.787

4.  Green tea extract catechin improves internal cardiac muscle relaxation in RCM mice.

Authors:  Xiaoqin Wang; Zhengyu Zhang; Gang Wu; Changlong Nan; Wen Shen; Yimin Hua; Xupei Huang
Journal:  J Biomed Sci       Date:  2016-06-28       Impact factor: 8.410

5.  Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation.

Authors:  Iúri Frias; Ana Rute Neves; Marina Pinheiro; Salette Reis
Journal:  Drug Des Devel Ther       Date:  2016-10-31       Impact factor: 4.162

6.  Epigallocatechin-3-Gallate Accelerates Relaxation and Ca2+ Transient Decay and Desensitizes Myofilaments in Healthy and Mybpc3-Targeted Knock-in Cardiomyopathic Mice.

Authors:  Felix W Friedrich; Frederik Flenner; Mahtab Nasib; Thomas Eschenhagen; Lucie Carrier
Journal:  Front Physiol       Date:  2016-12-05       Impact factor: 4.566

7.  Epigallocatechingallate attenuates myocardial injury in a mouse model of heart failure through TGF‑β1/Smad3 signaling pathway.

Authors:  Keyan Chen; Wei Chen; Shi Li Liu; Tian Shi Wu; Kai Feng Yu; Jing Qi; Yijun Wang; Hui Yao; Xiao Yang Huang; Ying Han; Ping Hou
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

8.  Ryanodine Receptor Type 2: A Molecular Target for Dichlorodiphenyltrichloroethane- and Dichlorodiphenyldichloroethylene-Mediated Cardiotoxicity.

Authors:  Kim M Truong; Wei Feng; Isaac N Pessah
Journal:  Toxicol Sci       Date:  2020-11-01       Impact factor: 4.849

Review 9.  Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca(2+)-sensitivity in the pathogenesis of cardiomyopathy.

Authors:  Andrew E Messer; Steven B Marston
Journal:  Front Physiol       Date:  2014-08-25       Impact factor: 4.566

10.  Molecular Defects in Cardiac Myofilament Ca2+-Regulation Due to Cardiomyopathy-Linked Mutations Can Be Reversed by Small Molecules Binding to Troponin.

Authors:  Alice Sheehan; Andrew E Messer; Maria Papadaki; Afnan Choudhry; Vladimír Kren; David Biedermann; Brian Blagg; Anuj Khandelwal; Steven B Marston
Journal:  Front Physiol       Date:  2018-03-27       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.